The objective of this research is to explore the impact of AT1RB therapy on depression and anxiety‐like behaviors triggered by menopause, as well as the levels of NLRP3, IL‐1β, BDNF, and oxidative stress in the hippocampal and prefrontal cortex tissues. Here, NLRP3 is linked to depressive symptom measurement.